CD274 and neoplasm: In addition to the combination strategy, radioisotope-labeled monoclonal antibodies which target immune checkpoints such as PD-L1 may also be effective cancer treatment strategies, because immune checkpoint-associated antibodies linked to cytotoxic nuclides not only have the function of immune modulation as an ICI, but only can selectively bind tumor antigens and release cytotoxic radiation. 213Bi-anti-hPD-L1 mAb was developed by Marisa Capitao et al 120.